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G and G Require Distinct Src-dependent Pathways to Activate
Rap1 and Ras*
John M. Schmitt‡ and Philip J. S. Stork§
From the Vollum Institute, and the Department of Cell and Developmental Biology, Oregon Health Sciences University,
Portland, Oregon 97201
The Src tyrosine kinase is necessary for activation of
extracellular signal-regulated kinases (ERKs) by the
-adrenergic receptor agonist, isoproterenol. In this
study, we examined the role of Src in the stimulation of
two small G proteins, Ras and Rap1, that have been
implicated in isoproterenol’s signaling to ERKs. We
demonstrate that the activation of isoproterenol of both
Rap1 and Ras requires Src. In HEK293 cells, isoproter-
enol activates Rap1, stimulates Rap1 association with
B-Raf, and activates ERKs, all via PKA. In contrast, the
activation by isoproterenol of Ras requires G sub-
units, is independent of PKA, and results in the phos-
phoinositol 3-kinase-dependent activation of AKT. In-
terestingly, -adrenergic stimulation of both Rap1 and
ERKs, but not Ras and AKT, can be blocked by a Src
mutant (SrcS17A) that is incapable of being phosphoryl-
ated and activated by PKA. Furthermore, a Src mutant
(SrcS17D), which mimics PKA phosphorylation at serine
17, stimulates Rap1 activation, Rap1/B-Raf association,
and ERK activation but does not stimulate Ras or AKT.
These data suggest that Rap1 activation, but not that of
Ras, is mediated through the direct phosphorylation of
Src by PKA. We propose that the 2-adrenergic receptor
activates Src via two independent mechanisms to medi-
ate distinct signaling pathways, one through Gs to
Rap1 and ERKs and the other through G to Ras and
AKT.
Stimulation of G protein-coupled receptors (GPCRs)1 trig-
gers a wide range of biochemical and physiological effects.
GPCR activation of heterotrimeric G proteins signals to dis-
tinct effector molecules through both the G protein  and 
subunits (1–3). Gs activation stimulates adenylyl cyclases to
elevate intracellular cAMP and activation of PKA. PKA can
regulate cell growth and differentiation through cross-talk with
the mitogen-activated protein kinase or ERK (extracellular
signal-regulated kinase) cascade (4–8).
In HEK293 cells, the 2-adrenergic receptor agonist isopro-
terenol stimulates endogenous receptors to activate ERKs
through a PKA-dependent pathway (9, 10). The activation by
isoproterenol of PKA has been shown to induce the activation of
Ras via a Src-dependent mechanism that is mediated by G
subunits (10–12). However, isoproterenol and PKA can also
activate Rap1 and ERKs in these cells (9). In NIH3T3 fibroblast
cells, PKA activation of Rap1 has been proposed to result from
the direct phosphorylation by PKA on the Src tyrosine kinase
(13). In NIH3T3 cells that do not express B-Raf, PKA and Rap1
antagonize Ras-dependent activation of ERKs (4, 7). In addi-
tion to antagonizing Ras, Rap1 can activate ERKs in cells that
express the mitogen-activated protein kinase kinase kinase
B-Raf (14). However, the contribution of Src in this action of
Rap1 has not been examined.
Because it has been shown that isoproterenol couples effi-
ciently to both Ras and Rap1 in HEK293 cells, this model
system provides an opportunity to examine the requirement of
Src in each process. Surprisingly, we found that Src was re-
quired for the activation of both Ras and Rap1 by isoproterenol.
However, it activated Rap1 and Ras through distinct
mechanisms.
MATERIALS AND METHODS
Reagents—Antibodies specific to phosphorylated-ERK (pERK) that
recognize phosphorylated ERK1 (pERK1) and ERK2 (pERK2) at resi-
dues threonine 183 and tyrosine 185 were purchased from New
England Biolabs (Beverly, MA). Antibodies specific to phosphorylated-
AKT (pAKT) that recognize phosphorylated AKT at residue threonine
308 were purchased from Cell Signaling (Beverly, MA). Antibodies to
Rap1, Raf-1, B-Raf, ERK2, c-Myc (9E10), Cbl, C3G, and agarose-
conjugated antibodies to Myc and hemagglutinin (HA) were purchased
from Santa Cruz Biotechnology Inc. (Santa Cruz, CA). Antibodies to HA
(12CA5) were purchased from Roche Molecular Biochemicals
(Indianapolis, IN). Anti-Ras antibodies were purchased from Upstate
Biotechnology (Lake Placid, NY). FLAG (M2) antibody, isoproterenol,
and epidermal growth factor (EGF), were purchased from Sigma. For-
skolin, PP2 (AG1879; 4-amino-5-(4-chlorophenyl)-7-(t-butyl)pya-
zolo[3,4-d]pyrimidine), LY294002 (2-(4-morpholinyl)-8-phenyl-4H-1-
bemzopyran-4-one), and N-(2-(p-bromocinnamylamino)ethyl)-5-
isoquinolinesulfonamide (H89) were purchased from Calbiochem
(Riverside, CA). Nickel-nitrilotriacetic acid-agarose was purchased
from Qiagen Inc. (Chatswoth, CA).
Cell Culturing Conditions and Treatments—HEK293, SYF, and
Src2 cells were purchased from ATCC and cultured in Dulbecco’s
modified Eagle’s medium plus 10% fetal calf serum, penicillin/strepto-
mycin, and L-glutamine at 37 °C in 5% CO2. Cells were maintained in
serum-free Dulbecco’s modified Eagle’s medium for 16 h at 37 °C in 5%
CO2 prior to treatment with various reagents for immunoprecipitation
assay, and Western blotting. In all experiments, cells were treated with
EGF (100 ng/ml), isoproterenol (10 M), or forskolin (10 M) for 5 min
unless otherwise indicated. PP2 (10 M), H89 (10 M), and LY294002
(10 M), were added to cells 20 min prior to treatment, unless otherwise
indicated.
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Western Blotting and Immunoprecipitation—Cell lysates and West-
ern blotting were prepared as described (7). Briefly, protein concentra-
tions were quantified using the Bradford protein assay. For detection of
Raf-1, ERK2, Myc-ERK2, FLAG, Rap1, Ras, pERK1/2, Cbl, C3G, and
pAKT, equivalent amounts of protein per treatment condition were
resolved by SDS-PAGE, blotted onto polyvinylidene difluoride (Milli-
pore Corp., Bedford, MA) membranes, and probed with the correspond-
ing antibodies according to the manufacturer’s guidelines. For immu-
noprecipitation of Myc-ERK2, Myc-Cbl, FLAG-Src, and HA-AKT equal
amounts of cell lysate per condition were precipitated at 4 °C for 4–6 h
in lysis buffer. Proteins were then resolved by SDS-PAGE, blotted onto
polyvinylidene difluoride membranes, and probed with the indicated
antibodies. In all cases, the results illustrated are from representative
experiments, repeated at least three times.
Plasmids and Transfections—The Src, SrcS17A, and SrcS17D plas-
mids were all generated as previously described (13). The SrcY527F
mutants were synthesized using PCR primers containing sequences
corresponding to the 5 end of the Src cDNA and sequences correspond-
ing to the 3 end of the Src cDNA, with the sequence corresponding to
tyrosine 527 replaced with that for phenylalanine (Y527F). SrcWT,
SrcS17A, and SrcS17D were amplified with these primers and sub-
cloned into a FLAG-pcDNA3 to create SrcY527F, SrcS17A/Y527F, and
SrcS17D/Y527F, respectively. Cbl-ct, encoding the carboxyl-terminal
amino acids 541 to 906, was provided by Dr. Brian Druker (OHSU,
Portland, OR). Hemagglutinin-tagged AKT (HA-AKT) was provided by
Dr. Thomas Soderling (Vollum Institute, Portland, OR). The transducin
(cone) cDNA was provided by the Guthrie cDNA Resource Center
(www.guthrie.org/AboutGuthrie/Research/cDNA). Seventy to eighty
percent confluent HEK293, SYF, or Src2 cells were co-transfected with
the indicated cDNAs using a LipofectAMINE 2000 kit (Invitrogen)
according to the manufacturer’s instructions. The control vector,
pcDNA3 (Invitrogen Corp.), was included in each set of transfections to
assure that each plate received the same amount of DNA. Following
transfection, cells were allowed to recover in serum-containing media
for 24 h. Cells were then starved overnight in serum-free Dulbecco’s
modified Eagle’s medium before treatment and lysis.
Affinity Assay for Rap1 Activation—A GST fusion protein of the
Rap1-binding domain of RalGDS (GST-RalGDS) was expressed in Esch-
erichia coli following induction by isopropyl-1-thio--D-galactopyrano-
side (GST-RalGDS was a gift from Dr. Johannes Bos, Utrecht Univer-
sity, The Netherlands). Cells were grown as described and were
stimulated at 37 °C for the indicated times and lysed in ice-cold lysis
buffer (50 mM Tris-Cl (pH 8.0), 10% glycerol, 1% Nonidet P-40, 200 mM
NaCl, 2.5 mM MgCl2, 1 mM phenylmethylsulfonyl fluoride, 1 M leupep-
tin, 10 g/ml soybean trypsin inhibitor, 10 mM NaF, 0.1 M aprotinin,
and 1 mM NaVO4). Active Rap1 was isolated as previously described by
Franke et al. (15). Equivalent amounts of supernatants (500 g) were
incubated with the GST-RalGDS-Rap1 binding domain coupled to glu-
tathione beads. Following a 1-h incubation at 4 °C, beads were pelleted
and rinsed three times with ice-cold lysis buffer, proteins were eluted
from the beads using 2 Laemmli buffer and applied to a 12% SDS-
polyacrylamide gel. Proteins were transferred to polyvinylidene difluo-
ride membrane, blocked in 5% milk for 1 h, and probed with either
-Rap1/Krev-1 or FLAG antibody overnight at 4 °C, followed by incu-
bation with an horseradish peroxidase-conjugated anti-rabbit IgG an-
tibody (or an anti-mouse IgG for anti-FLAG Western blots). Proteins
were detected using enhanced chemiluminescence. All experiments
were repeated at least three times and representative gels are shown.
Affinity Assay for Ras Activation—HEK293 cells were grown as de-
scribed, stimulated, and lysed in ice-cold lysis buffer. Activated Ras was
assayed as previously described (7). Briefly, equivalent amounts of
lysates from stimulated cells were incubated with GST-Raf1-RBD (Ras-
binding domain) as specified by the manufacturer (Upstate Biotechnol-
ogy, Lake Placid, NY). Proteins were eluted with 2 Laemmli buffer
and applied to a 12% SDS-polyacrylamide gel. Proteins were trans-
ferred to a polyvinylidene difluoride membrane, blocked at room tem-
perature for 1 h in 5% milk, and probed with either Ras or FLAG
antibody overnight at 4 °C, followed by horseradish peroxidase-conju-
gated anti-mouse secondary antibodies. Proteins were detected using
enhanced chemiluminescence. All experiments were repeated at least
three times and representative gels shown.
Nickel Affinity Chromatography—HEK293 cells were transfected us-
ing LipofectAMINE reagent with polyhistidine-tagged Rap1 (His-Rap1)
as previously described (7, 9). Briefly, cells were lysed in ice-cold buffer
containing 1% Nonidet P-40, 10 mM Tris, pH 8.0, 20 mM NaCl, 30 mM
MgCl2, 1 mM phenylmethylsulfonyl fluoride, and 0.5 mg/ml aprotinin
and supernatants were prepared by low speed centrifugation. Trans-
fected His-tagged proteins were precipitated from supernatants con-
taining equal amounts of protein using nickel-nitrilotriacetic acid-aga-
rose and washed with 20 mM imidazole in lysis buffer and eluted with
500 mM imidazole and 5 mM EDTA in phosphate-buffered saline. The
eluates containing His-tagged proteins were separated on SDS-PAGE
and Raf-1 proteins were detected by Western blotting (7, 9).
RESULTS
In HEK293 cells, isoproterenol activated endogenous Rap1
in a PKA-dependent manner, as previously shown (9). Inter-
estingly, this activation required Src family kinases (SFKs) as
it was blocked by the inhibitor PP2 (16) (Fig. 1A). Isoproterenol
also activated endogenous Ras via SFKs, but this proceeded
through a PKA-independent pathway (Fig. 1B).
To determine which SFK was mediating these effects, we
utilized a pair of cell lines derived from mouse embryo fibro-
blasts that lack SFKs. One cell line, SYF, was developed from
mice deficient in the genes encoding Yes, Fyn, and Src, and has
been shown to lack SFK activity (17). The second cell line,
Src2, originated from mice deficient in only Yes and Fyn and
maintained the wild type Src gene and normal Src protein
levels (17). The ability of isoproterenol to activate Rap1 was
absent in SYF cells (Fig. 2A), but was retained in Src2 cells
(Fig. 2B). Similarly, the ability of isoproterenol to activate Ras
was also absent in SYF cells (Fig. 2C), but was retained in
Src2 cells (Fig. 2D). Additionally, both actions of isoproterenol
could be reconstituted by transfecting wild type Src (SrcWT)
into SYF cells (Fig. 2, A and C). Taken together, these data
demonstrate that Src is required for activation by isoproterenol
of both Ras and Rap1 in these cells.
The ability of cAMP to activate Rap1 in selected cell types
has recently been shown to require Src and PKA (13), through
FIG. 1. Activation by isoproterenol of Rap1 and Ras. A, the
activation by isoproterenol of the small G protein Rap1 is PKA- and
SFK-dependent. HEK293 cells received no pretreatment or were pre-
treated with H89 or PP2, and then treated with isoproterenol, as
indicated (see “Experimental Procedures”). Cell lysates were prepared
as described under “Experimental Procedures” and endogenous GTP-
loaded Rap1 was examined by Western blot (upper panel). The lower
panel is a Western blot demonstrating equivalent loading of total Rap1
in whole cell lysates used for the Rap1 assay, using the Rap1 antibody.
B, the activation by isoproterenol of Ras is SFK-dependent and PKA-
independent. HEK293 cells were treated as in A. Cell lysates were
examined for endogenous GTP-loaded Ras as described under “Exper-
imental Procedures” and probed for Ras-GTP (upper panel). The lower
panel demonstrates that equivalent amounts of total Ras in whole cell
lysates were loaded, as evidenced by anti-Ras Western blot.
the PKA-dependent phosphorylation of Src at serine 17 (Ser17).
However, the requirement of Ser17 phosphorylation in hormo-
nal signaling to Ras, Rap1, and ERKs has not been examined.
To address the requirement of Ser17 phosphorylation in Ras
and Rap1 signaling, we examined their activation by isoprot-
erenol in cells expressing one of two SrcS17 mutants. Unlike
SrcWT, the expression of a mutant Src, where Ser17 was re-
placed with an alanine (SrcS17A), was unable to reconstitute
the activation by isoproterenol of Rap1 (Fig. 2A). Moreover,
expression of a second Src mutant in which Ser17 was replaced
with an aspartate (SrcS17D) resulted in constitutive activation
of Rap1 (Fig. 2A). This is similar to previous results from cells
treated with forskolin, an activator of adenylyl cyclases (13).
Importantly, this activation of Rap1 by SrcS17D was not fur-
ther stimulated by isoproterenol, suggesting that SrcS17D was
maximally activating Rap1. The expression of SrcS17A in
Src2 cells inhibited the activation by isoproterenol of Rap1
(Fig. 2B), suggesting that SrcS17A was interfering with signals
through endogenous Src in these cells. In contrast to the re-
sponse in SYF cells, the activation of Rap1 by SrcS17D and
isoproterenol in Src2 cells was additive (Fig. 2B), presumably
reflecting the contribution of the activation by isoproterenol of
endogenous Src.
Conversely, the activation by isoproterenol of Ras was not
blocked by these mutants. In SYF cells, expression of SrcS17A
reconstituted Ras activation by isoproterenol to a level similar
to that seen using SrcWT (Fig. 2C). Interestingly, in Src2 cells,
SrcS17A did not interfere with Ras activation by isoproterenol
but appeared to enhance Ras activation in these cells (Fig. 2D).
On the other hand, SrcS17D was unable to activate Ras in
either cell line (Fig. 2C and D). These data suggest that
SrcS17A was capable of mediating a Src-dependent pathway to
Ras, demonstrating that the interference of Rap1 activation by
SrcS17A in Src2 cells was selective. Moreover, SrcS17D did
not potentiate the stimulation by isoproterenol of Ras in Src2
cells (Fig. 2D), suggesting that, unlike SrcS17A, SrcS17D alone
could not participate efficiently in pathways to activate Ras.
Surprisingly, SrcS17D could activate Ras to a moderate de-
gree in SYF cells, but only in conjunction with isoproterenol
(Fig. 2C). This appears inconsistent with the selectivity of
SrcS17D toward Rap1. One mechanism by which SrcS17D
might function as an activator of Rap1 is to bind endogenous
FIG. 2. Rap1 and Ras activation by isoproterenol require Src kinase. A and B, PKA phosphorylation of serine 17 on Src is necessary and
sufficient for Rap1 activation by isoproterenol. SYF cells (A) or Src2 cells (B) were transfected with FLAG-Rap1 and the indicated Src cDNAs, or
pcDNA3 vector alone. Cells were stimulated with isoproterenol or left untreated, as indicated. Cell lysates were examined for active GTP-loaded
Rap1 (Flag-Rap1-GTP). C and D, phosphorylation of Src by PKA on serine 17 is not required for Ras activation by isoproterenol. SYF cells (C) or
Src2 cells (D) were transfected with FLAG-Ras and the indicated Src cDNAs or vector alone. Cells were stimulated with isoproterenol or left
unstimulated, and cell lysates were examined for active GTP-loaded Ras (Flag-Ras-GTP). In all experiments, the level of FLAG-Src and
FLAG-Rap1 or FLAG-Ras are shown in the middle and lower panels.
proteins that target Src toward Rap1. In this model, it might be
expected that the selectivity of SrcS17D toward Rap1 would not
be apparent if it was overexpressed. To examine further the
finding that SrcS17D could participate in the activation by
isoproterenol of Ras in SYF cells, we compared the effect of
increasing concentrations of both transfected SrcWT and
SrcS17D in these cells (Fig. 3). Increasing amounts of trans-
fected SrcWT potentiated the activation by isoproterenol of Ras
at all concentrations examined, especially at low to moderate
doses (Fig. 3). In contrast, the ability of SrcS17D to carry a
signal from isoproterenol to Ras was only apparent at the
highest level of expression examined. Therefore, whereas acti-
vation by SrcS17D of Rap1 was not further enhanced by iso-
proterenol, isoproterenol-dependent activation of Ras by
SrcS17D was contingent on overexpression. These data are
consistent with a model that SrcS17D interacts with an endog-
enous protein that channels Src toward a Rap1 pathway, but
that when overexpressed, SrcS17D can act independently of
this pathway.
Next, we examined the mechanism of ERK activation by
isoproterenol in HEK293 cells (9). The ability of isoproterenol
to activate Rap1 was modestly enhanced following transfection
of SrcWT, but was completely blocked following transfection of
SrcS17A (Fig. 4A). These data suggest that SrcS17A can inter-
fere with the ability of endogenous Src to mediate the activa-
tion by isoproterenol of Rap1 in HEK293 cells. Expression of
SrcS17D activated Rap1 constitutively in these cells, and this
was not significantly enhanced by isoproterenol (Fig. 4A).
Upon its activation, Rap1 binds the effector B-Raf to activate
ERKs (5, 9). This recruitment of B-Raf has been used as an
index of Rap1 activation in a variety of cell types (9, 18–20).
The ability of isoproterenol to stimulate the association of B-
Raf with Rap1 was blocked by SrcS17A. SrcS17D stimulated
the association of B-Raf with Rap1, and this was modestly
enhanced by isoproterenol (Fig. 4B). Taken together, these data
demonstrate that phosphorylation of Ser17 is required for both
Rap1 activation and function.
It has previously been suggested that the activation by cAMP
of Rap1 by forskolin requires Cbl and the Rap1 exchanger C3G,
in NIH3T3 cells (9, 13). To examine whether a similar mecha-
nism might underlie signaling from GPCRs, we examined iso-
proterenol signaling in HEK293 cells expressing two interfer-
ing mutants: Cbl-ct, a carboxyl-terminal fragment that blocks
Cbl function (13), and CBR, a truncated protein containing the
Crk-binding region of C3G that blocks C3G binding to Crk (9,
21). The ability of isoproterenol to induce the recruitment by
Rap1 of B-Raf was blocked by both Cbl-ct and CBR (Fig. 4B).
Isoproterenol also induced the association of Cbl with SrcWT
but not SrcS17A (Fig. 4C). SrcS17D induced this association in
the absence of isoproterenol (Fig. 4C). Similarly, isoproterenol
induced an association between C3G and transfected Cbl that
was mimicked by SrcS17D, but not SrcS17A (Fig. 4D). In
addition, we detected an isoproterenol-dependent association
between wild type Src and C3G that was also mimicked by
SrcS17D (Fig. 4E). This suggests that the association of Cbl/
C3G with Src following isoproterenol stimulation was depend-
ent on phosphorylation of Ser17.
Mutation of tyrosine 527 of Src to phenylalanine (Y527F)
produces a constitutively active (oncogenic) Src by eliminating
the inhibitory phosphorylation at Tyr527 (22, 23). This mutant
constitutively activated both Ras and Rap1 in HEK293 cells
(Fig. 5, A and B). However, introduction of S17A in SrcY527F
created a new mutant (SrcS17A/Y527F) that was unable to
activate Rap1, whereas SrcS17D/Y527F activated Rap1 consti-
tutively (Fig. 5A). Both SrcS17A/Y527F and SrcS17D/Y527F
could activate Ras, suggesting that S17A selectively interfered
with oncogenic activation by Src of Rap1. In addition, both
Cbl-ct and CBR interfered with Rap1 activation, but had no
effect on Ras activation, suggesting that the action of endoge-
nous Cbl and C3G were specific for Rap1.
The inability of SrcS17A to interfere with Ras signaling was
seen by examining hormonally activated Src in HEK293 cells.
Both SrcWT and SrcS17A, but not by SrcS17D, modestly en-
hanced the activation by isoproterenol of Ras (Fig. 6A). Ras
activation by isoproterenol is thought to be mediated via G
(10, 24). This was confirmed by experiments in HEK293 cells
that showed that the activation by isoproterenol of Ras was
blocked by expression of a truncated -adrenergic receptor
kinase (ARK-ct) (Fig. 6A), and by expression of transducin, a
retinal-specific Gs subunit (Fig. 6B). Both ARK-ct and trans-
ducin block signals generated from  subunits by binding to
endogenous  (2, 25). As a control, we show that EGF activa-
tion of Ras was not blocked by expression of transducin (Fig.
6B). In contrast, transducin did not block Rap1 activation by
isoproterenol (Fig. 6C). Taken together, these data suggest that
while Ras and Rap1 are both activated by Src-dependent mech-
anisms downstream of the -adrenergic receptor, only Ras ac-
tivation involves G.
To examine the downstream consequences of Src-dependent
signaling in HEK293 cells, we measured ERK activation, using
pERK antibodies (pERK1/2). Activation by isoproterenol of
ERKs required both PKA and SFKs, as phosphorylation of
ERK was prevented by both H89 and PP2 (Fig. 7A). Similar
results were seen using forskolin (Fig. 7B). In contrast, the
phosphoinositol 3-kinase (PI3K) inhibitor, LY294002, did not
block ERK phosphorylation (Fig. 7A). Expression of SrcS17A
blocked the activation by isoproterenol of ERKs (Fig. 8A), and
SrcS17D constitutively activated ERKs (Fig. 8B), consistent
with a model that the activation by Src of Rap1 was necessary
and sufficient for the activation by isoproterenol of ERKs in
these cells. Moreover, isoproterenol was unable to further ac-
tivate ERKs in SrcS17D-expressing cells, suggesting that the
phosphorylation of SrcS17 was the predominant mode of ERK
activation by isoproterenol.
Previously, we and others have suggested that Ras was not
required for ERK activation by isoproterenol in HEK293 cells
(9, 20). This is despite the fact that Ras is activated by isopro-
terenol (Fig. 6, A and B). To examine the physiological role of
Ras signaling in these cells, we examined a well known Ras
effector, PI3K and its target, AKT (26). Isoproterenol activated
AKT, as measured by phosphorylation-specific antibodies to
phosphothreonine 308 (pAKT) (Fig. 9A). This phosphorylation
required PI3K as LY294002 blocked isoproterenol-induced
phosphorylation at this site (Fig. 9A). Moreover, this phospho-
FIG. 3. Concentration curve for the activation by Src of Ras in
isoproterenol-treated SYF cells. The activation by Src of Ras is
dose-dependent. SYF cells were transfected with FLAG-Ras (5 g) and
FLAG-SrcWT or FLAG-SrcS17D at the indicated plasmid concentra-
tions. Cells were left unstimulated or treated with isoproterenol, as
indicated, and cell lysates were examined for active GTP-loaded Ras
(Flag-Ras-GTP). The levels of FLAG-Src and FLAG-Ras are shown in
the middle and lower panels, respectively.
rylation was blocked by PP2, but not H89, suggesting the
requirement of SFKs, but not PKA (Fig. 9A).
The requirement for Ras in the activation by isoproterenol of
AKT in HEK293 cells was demonstrated by the ability of the
interfering mutant of Ras, RasN17, to block this effect (Fig. 9B)
(7). To examine the requirement of Src in greater detail, we
FIG. 4. PKA phosphorylation of Src mediates Rap1 activation and its association with B-Raf following isoproterenol stimulation.
A, serine 17 of Src mediates the activation by isoproterenol of Rap1. HEK293 cells were transfected with pcDNA3, FLAG-Rap1, or the indicated
Src plasmids. Cells were treated with isoproterenol as indicated, and cell lysates were examined for active Rap1 (Flag-Rap1-GTP, upper panel).
The lower panel demonstrates similar expression levels of FLAG-Rap1 protein. B, B-Raf association with Rap1 following isoproterenol stimulation
requires Src, Cbl, and C3G. HEK293 cells were transfected with His-tagged Rap1 (His-Rap1), in the presence or absence of SrcS17A, SrcS17D,
CBR, and Cbl-ct as indicated. Cells were treated with isoproterenol, and cell lysates were passed over a nickel column to isolate His-Rap1 and
associated proteins, and eluates were probed by Western blotting for endogenous B-Raf, as described under “Experimental Procedures” (upper
panel). The lower panel shows a Western blot indicating that similar protein amounts of transfected His-Rap1 protein were assayed in each
treatment condition. C, isoproterenol induces the association of Src with Cbl in HEK293 cells. HEK293 cells were transfected FLAG-tagged SrcWT,
SrcS17A, and SrcS17D, as indicated. Cells were treated with isoproterenol and equivalent amounts of lysates immunoprecipitated with FLAG
antibody and the presence of endogenous Cbl within the eluates was examined by Western blot (upper panel). The lower panel shows a Western
blot indicating that similar protein amounts of FLAG-Src proteins were assayed in each treatment condition. D, isoproterenol induces the
association of C3G with Cbl in HEK293 cells. HEK293 cells were transfected with Myc-Cbl and either SrcS17A or SrcS17D, as indicated. Cells were
treated with isoproterenol or left untreated and equal amounts of lysates immunoprecipitated with Myc antibody and the presence of endogenous
C3G within the eluates were examined by Western blot (upper panel). The lower panel shows a Western blot indicating that similar protein
amounts of Myc-Cbl proteins were assayed in each treatment condition. E, isoproterenol induces the association of Src with C3G in HEK293 cells.
HEK293 cells were transfected FLAG-tagged SrcWT or SrcS17D and treated with isoproterenol as indicated. Equivalent amounts of lysates were
immunoprecipitated with FLAG antibody and the presence of endogenous C3G within the eluates was examined by Western blot (upper panel).
The lower panel shows a Western blot indicating that similar protein amounts of FLAG-Src proteins were assayed in each treatment condition.
expressed the Src mutants SrcS17A and SrcS17D in these cells.
SrcS17A did not block the activation of AKT by isoproterenol
nor did SrcS17D result in constitutive activation of AKT. Like
their actions on Ras, SrcS17A and SrcWT enhanced phospho-
rylation of AKT to similar levels, suggesting that, although
overexpression of SrcS17A selectively interfered with effectors
of Rap1, it mimicked the action of wild type Src on effectors
downstream of Ras.
DISCUSSION
The small G proteins Ras and Rap1 have both been proposed
to mediate the ability of cAMP to activate ERKs (5, 8, 10,
27–29). In many cell types, PKA inhibits Ras activation of Raf-1
and ERKs (6, 30, 31). The studies shown here, and previous
studies (9), suggest that PKA can activate signals to B-Raf and
ERKs while inhibiting Ras-dependent activation of Raf-1. The
results from this study differ from other results performed in
HEK293 cells that suggest that the activation by isoproterenol
of ERKs requires both PKA and Ras-dependent activation of
Raf-1 (10). It is possible that these distinct results reflect dif-
ferences among clonal isolates of HEK293 cells in their expres-
sion of B-Raf and/or the protein 14-3-3, whose levels may de-
termine the ability of cAMP to activate B-Raf (28).
The studies shown here describe a novel mechanism of the
activation by Src of ERKs, via Rap1 and B-Raf. This activation
was mediated by PKA and Rap1 and was blocked by phospho-
rylation site mutants of Src (13). We propose that Src activa-
tion of ERK via Rap1 requires the phosphorylation of Src by
PKA. Hormonal activation of ERKs via PKA has previously
been shown to use Rap1/B-Raf in a number of systems, includ-
ing those involving thyroid stimulating hormone (32) and iso-
proterenol (29), although the role of Src was not examined in
those studies. In one system examining adenosine activation of
ERKs in Chinese hamster ovary cells (33), both cAMP and
agonists activated Rap1/B-Raf and ERKs. ERK activation in
this system required both PKA (33) and Src (20). In addition, a
few examples have been reported of an SFK dependence of
FIG. 5. Constitutively active Src (SrcY527F) activates both Ras
and Rap1. A, SrcY527F activates Rap1. HEK293 cells were transfected
with FLAG-tagged Rap1 (Flag-Rap1), in the presence or absence of
pcDNA3, SrcY527F, SrcS17A/Y527F, SrcS17D/Y527F, CBR, and Cbl-ct
as indicated. Cell lysates were assayed for FLAG-Rap1 activation (Flag-
Rap1-GTP), as described above. The middle and lower panels show
Western blots indicating the expression of FLAG-Src and FLAG-Rap1,
respectively, in each treatment condition. B, SrcY527F activates Ras.
HEK293 cells were transfected with FLAG-tagged Ras (Flag-Ras), in
the presence or absence of pcDNA3, SrcY527F, SrcS17A/Y527F,
SrcS17D/Y527F, CBR, and Cbl-ct as indicated. Cell lysates were as-
sayed for FLAG-Ras activation (Flag-Ras-GTP), as described above.
The middle and lower panels show Western blots indicating the expres-
sion of FLAG-Src and FLAG-Ras, respectively, in each treatment
condition.
FIG. 6. Isoproterenol activation of Rap1 and Ras occurs
through distinct heterotrimeric G protein subunits. A, Ras acti-
vation by isoproterenol is independent of PKA phosphorylation of Src.
HEK293 cells were transfected with FLAG-Ras in the presence or
absence of SrcWT, SrcS17A, SrcS17D, or ARK-ct, as indicated, and
stimulated with isoproterenol. Cell lysates were examined for active
Ras (Flag-Ras-GTP) as indicated in the upper panel. The lower panel
demonstrates similar expression levels of total FLAG-Ras protein. B,
isoproterenol activation of Ras occurs via the  subunits of the -ad-
renergic receptor. HEK293 cells were transfected with FLAG-Ras in the
presence or absence of the transducin cDNA and stimulated with either
isoproterenol or EGF (as a control), as indicated. The activation of
FLAG-Ras (Flag-Ras-GTP) is shown in the upper panel. Expression of
total FLAG-Ras is indicated in the lower panel. C, Rap1 activation by
isoproterenol does not require G subunits. HEK293 cells were trans-
fected with FLAG-Rap1, with and without transducin, and stimulated
with isoproterenol, as indicated. Cell lysates were examined for the
activation of FLAG-Rap1 (Flag-Rap1-GTP, upper panel) as well as for
equivalent FLAG-Rap1 expression within whole cell lysates (lower
panel).
activation by PKA of ERKs, in astrocytic cells (34), neuronal
cells (35), and adipocytes (36, 37). It will be important to de-
termine whether PKA phosphorylation of Src participates in
Rap1/B-Raf signaling to ERKs in these systems as well.
Src can activate ERKs via Ras in other cell types (3). For
example, Src can trigger Shc phosphorylation and subsequent
activation of the Ras exchanger SOS (38, 39). Src can also
activate Ras through the transactivation of the EGF receptor
and related receptors following stimulation of GPCRs coupled
to either Gi or Gq (12, 40–42). In one report, transactivation of
the EGF receptor occurred following stimulation of the 2-
adrenergic receptor (43) via  subunits and the assembly of
multiprotein complexes at clathrin-dependent sites of endocy-
tosis (44). Direct association of Src with the adaptor -arrestin
has been shown to be involved in the clathrin-mediated endo-
cytic event (45, 46). The role of PKA in this model of Src
activation is to phosphorylate the 2 receptor itself, inducing a
switch from G to Gi and a subsequent activation of Src com-
plex via Gi (10), although recent studies disagree as to the
importance of PKA phosphorylation of the 2 receptor in the
activation by isoproterenol of ERK (47, 48).
The studies presented here using HEK293 cells suggest that
isoproterenol activation of ERKs required PKA, Src, and Rap1.
Specifically, SrcS17A interfered with the activation by isopro-
terenol of Rap1 but not that of Ras. More importantly, SrcS17D
maximally activated ERKs, with no additional activation was
provided by isoproterenol. This observation strongly suggests
that the major signaling pathway used by isoproterenol to
activate ERKs in these cells is via the phosphorylation of Src at
Ser17 by PKA.
The Src tyrosine kinase has been shown to regulate a diverse
number of cellular effects including stimulating (49–51) and
inhibiting cell growth (13), regulating cell adhesion (52, 53),
and regulating apoptosis (54, 55). Because of the many distinct
cellular functions of Src, it is likely that the ability of Src to
activate specific pathways is tightly regulated. The studies
presented here provide some insight into the signaling speci-
ficity of Src. We propose that activation of the -adrenergic
receptor triggers two concurrent Src-dependent pathways, in-
volving Gs to activate Rap1 and Gs to activate Ras, respec-
tively. Whereas Src is required for both Rap1 and Ras activa-
tion, only Rap1 activation required PKA (Fig. 1). Sequestration
of  subunits blocked only Ras activation, not Rap1. Taken
together, these data suggest that Gs and PKA were responsi-
ble for Rap1 activation, whereas , but not PKA, was respon-
sible for Ras activation. Other studies have suggested a PKA
dependence of the activation by isoproterenol of Ras in these
(10) and other cell types (47).
We have identified specific Src mutants that can selectively
block (SrcS17A) or enhance (SrcS17D) the activation of Rap1,
without effect on the simultaneous activation of Ras. These
studies support a model whereby the mechanism of activating
FIG. 7. cAMP activation of ERKs is both PKA- and Src-depend-
ent. A, activation by isoproterenol of endogenous ERKs requires both
PKA and Src. HEK293 cells received no pretreatment or were pre-
treated with H89, PP2, or LY294002, and stimulated with isoprotere-
nol, as indicated. Cell lysates were analyzed by Western blotting for
pERK1/2 (pERK1/pERK2, upper panel) or total ERK2 as a control for
protein loading (lower panel). B, forskolin activation of endogenous
ERKs requires both PKA and Src. HEK293 cells received no pretreat-
ment or were pretreated with H89 or PP2 and stimulated with either
forskolin or EGF (positive control), as indicated. Cell lysates were
examined by Western blotting for pERK1/2 (pERK1/pERK2, upper
panel) or total ERK2 as a control for protein loading (lower panel).
FIG. 8. Activation by isoproterenol of ERKs requires serine 17
phosphorylation of Src. A, PKA phosphorylation of Src on serine 17
is necessary for ERK activation by cAMP. HEK293 cells were trans-
fected with Myc-ERK2 in the presence or absence of SrcS17A, and
stimulated with isoproterenol, as indicated. Myc-ERK2 was immuno-
precipitated from cell lysates using an agarose-coupled Myc antibody
followed by Western blotting for phospho-ERK (pMycERK2, upper
panel) or total Myc-ERK2 with a Myc antibody, as a control for protein
loading (lower panel). B, expression of SrcS17D mimics the activation
by isoproterenol of ERKs. HEK293 cells were transfected with Myc-
ERK2 in the presence or absence of SrcS17D, and stimulated with
isoproterenol, as indicated. Cell lysates were examined as in A for
phosphorylated pMyc-ERK2 and expression of pMyc-ERK2.
FIG. 9. AKT activation by isoproterenol is PKA-independent
but requires both Ras and G. A, activation by isoproterenol of
AKT proceeds through Src and PI3K but not PKA. HEK293 cells re-
ceived no pretreatment or were pretreated with H89, PP2, or
LY294002, and stimulated with isoproterenol, as indicated. Cell lysates
were analyzed by Western blotting for phospho-AKT (pAKT 308, upper
panel) or total AKT as a control (lower panel). B, AKT activation by
isoproterenol is Ras- and -dependent. HEK293 cells were transfected
with HA-AKT in the presence or absence of SrcWT, SrcS17A, SrcS17D,
RasN17, or ARK-ct, and stimulated with isoproterenol, as indicated.
Similar amounts of cell lysate (as determined by protein concentra-
tions) were immunoprecipitated using an agarose-coupled HA antibody
followed by Western blotting for phospho-AKT (pHA-AKT (308), upper
panel) or total HA-AKT with an HA antibody (lower panel).
Src dictates the choice of effector pathways, and identify PKA
phosphorylation of Src as a potential mechanism to direct Src
signals toward Rap1. This is consistent with a recent report
that suggested that SrcS17A selectively interfered with ERK
activation by cAMP (20). This study, however, did not examine
the action of this mutant on either Ras or Rap1 activation.
Although neither isoproterenol nor SrcS17D could activate
Ras in SYF cells, isoproterenol could activate Ras modestly
when SrcS17D was expressed to high levels. The requirement
of isoproterenol for SrcS17D activation of Ras suggests that
SrcS17D was not acting constitutively, but was dependent on
additional signals generated downstream of the -adrenergic
receptor. Moreover, this action was only seen at high levels of
SrcS17D expression, suggesting that some endogenous pro-
tein(s) may bind SrcS17D and insulate it from participating in
Ras activation when expressed at lower levels.
What mechanism allows SrcS17D to direct Src kinase activ-
ity toward selective substrates? It is possible that the proximity
of the Ser17 site to the NH2-terminal myristoylation of Src may
allow this phosphorylation (or aspartate residue) to influence
proper membrane targeting. Indeed, one previous study sug-
gested that the phosphorylation by PKA of Src may be suffi-
cient to redirect membrane localization of Src (56). However,
the ability of Src mutants to interfere with Rap1 activation
suggests that the cellular interactions that are disrupted by
this mutant are saturatable. In addition, that SrcS17D is con-
stitutively active suggest that it is not just being relocalized,
but is activated as well. It is also possible that this phospho-
rylation may influence the binding of additional docking/adap-
tor proteins that influence both the activity of Src and choice of
substrates (54, 57–62).
The ability of Src and SYFs to activate Rap1 via C3G/Crk has
been demonstrated in multiple systems (13, 63, 64). In some
cells, this is mediated via a Cbl adaptor protein (13, 65–67).
Studies shown here identify Cbl as a potential target of acti-
vation by Src of Rap1. Moreover, the ability of Cbl to associate
with either Src or C3G was mimicked by SrcS17D but not
SrcS17A. Although Cbl has been proposed to mediate Src-de-
pendent signals downstream of receptors (68, 69), this is the
first report of such a pathway downstream of GPCRs. Future
studies will examine whether these or additional proteins reg-
ulate Src function following phosphorylation by PKA.
The action of Cbl proposed here is similar to that seen for the
Cbl-associated protein, Cas and the related protein Sin. In
certain cells, Src can activate the adaptor Cas (64), or the
related protein Sin (63, 70) to activate a Crk/C3G/Rap1 path-
way. Interestingly, in HEK293 cells, activation of Src by Sin
activates Crk/C3G/Rap1, but not Ras. However, expression of
the oncogenic Src mutant, SrcY527F, activates Ras signaling
pathways as well as Rap1 (63). Here, we confirm that SrcY527F
can activate both Ras and Rap1 and demonstrate that the
activation of Rap1, but not Ras, required Ser17 and C3G. There-
fore, Src-dependent signals can be directed down specific path-
ways in a stimulus and cell type-specific manner. The molecu-
lar mechanisms by which Src is channeled toward selective
signaling pathways are largely unknown.
-Adrenergic receptor activation of Ras also required Src,
but unlike Rap1, Ras activation required Gs. This activation
of Ras was capable of coupling positively to AKT. AKT is a
serine/threonine kinase known to participate in a variety of
cellular effects including cell survival, adhesion, and cell
growth (26, 71–73). Multiple GPCRs have been shown to reg-
ulate AKT activation via PI3K (74–76). Data presented here
identify a requirement for Ras because the activation by iso-
proterenol of AKT was independent of PKA and unaffected by
SrcS17A. This is consistent with a recent report suggesting
that cAMP/PKA/Rap1 does not activate AKT (77).
Studies in both COS-7 cells and HEK293 cells have also
shown that AKT can be activated by isoproterenol and the 
subunits of heterotrimeric G proteins through both Ras and
PI3K, but not by constitutively active Gs (75, 76). A more
recent study has confirmed that -adrenergic receptor stimu-
lation activates AKT independently of PKA, and through a -
and PI3K-dependent mechanism (7). In our study, interfering
with Src function using SrcS17A had no effect on the ability of
Src to couple G to Ras and AKT. Rather, overexpression of
SrcS17A, like wild type Src, potentiated Ras signaling to AKT.
Therefore, the ability of SrcS17A to act as an interfering mu-
tant was selective for Rap1. Taken together, this data would
suggest that in HEK293 cells, the -adrenergic receptor is
capable of activating AKT through a pathway involving , Src,
Ras, and PI3K.
In summary, we have shown that stimulation of HEK293
cells with isoproterenol activated two independent pathways
mediated by Gs to PKA/Rap1/ERK and G to Ras/AKT, re-
spectively. Both pathways required Src, but only signaling
from Gs/PKA to Rap1 and ERKs required the phosphorylation
of Src at serine 17. These results imply a model where Src can
specifically couple to downstream effectors depending on its
mode of activation, and suggest that Src itself simultaneously
regulates multiple -adrenergic pathways via distinct
pathways.
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